ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONCS OncoSec Medical Incorporated

0.2772
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
OncoSec Medical Incorporated NASDAQ:ONCS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.2772 0.265 0.2651 0 01:00:00

OncoSec to Host Fourth Quarter and Fiscal Year End Financial Results Conference Call on October 13, 2016

30/09/2016 11:01am

PR Newswire (US)


OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more OncoSec Medical Charts.

SAN DIEGO, Sept. 30, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal fourth quarter and fiscal year end 2016 financial results conference call on Thursday, October 13 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 91814044. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events.  

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

Contact
Sophia Ononye, PhD MPH MBA
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

OncoSec Medical, Inc. Logo. Please visit http://oncosec.com/ for more information.

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-host-fourth-quarter-and-fiscal-year-end-financial-results-conference-call-on-october-13-2016-300337030.html

SOURCE OncoSec Medical Incorporated

Copyright 2016 PR Newswire

1 Year OncoSec Medical Chart

1 Year OncoSec Medical Chart

1 Month OncoSec Medical Chart

1 Month OncoSec Medical Chart

Your Recent History

Delayed Upgrade Clock